uploads/2018/08/close-up-1853400_1280.jpg

Update on Roche’s Oncology Drugs: Tarceva, Cotellic, and Erivedge

By

Updated

Tarceva’s revenue trends

Roche’s (RHHBY) Tarceva generated revenues of 298.0 million Swiss francs in the first half compared to 436.0 million Swiss francs in the first half of 2017, which reflected an ~32.0% YoY (year-over-year) decline at CER (constant exchange rates).

In the first half, in the United States, Europe, and Japan, Tarceva generated revenues of 126.0 million Swiss francs, 61.0 million Swiss francs, and 39.0 million Swiss francs, respectively, which reflected YoY declines of ~44.0%, ~23.0%, and ~15.0% at CER.

Tarceva reported revenues of 157.0 million Swiss francs in the second quarter, reflecting ~31.0% YoY decline at CER. Tarceva is used in the treatment of individuals with metastatic non-small cell lung cancer and advanced pancreatic cancer.

Article continues below advertisement

Cotellic’s revenue trends

Cotellic generated revenues of 32.0 million Swiss francs in the first half, reflecting ~9.0% YoY growth at CER. In the first half, in the United States and European markets, Cotellic generated revenues of 9.0 million Swiss francs and 18.0 million Swiss francs, respectively.

In the second quarter, Cotellic generated revenues of 17.0 million Swiss francs, which reflected ~13.0% YoY growth at CER. In the United States and European markets, Cotellic generated revenues of 5.0 million Swiss francs and 9.0 million Swiss francs,

In the melanoma drugs market, Cotellic’s peers include Novartis (NVS) Tafinlar + Mekinist and Bristol-Myers Squibb’s (BMY) Yervoy. In the second quarter, Novartis (NVS) Tafinlar + Mekinist and Bristol-Myers Squibb’s (BMY) Yervoy reported revenues of $284.0 million and $315.0 million, respectively.

Erivedge’s revenue trends

Roche’s Erivedge generated revenues of 126.0 million Swiss francs in the first half, which reflected ~6.0% YoY growth at CER. In the United States and European markets, Erivedge reported first-half revenues of 76.0 million Swiss francs and 37.0 million Swiss francs, respectively.

In the second quarter, Erivedge generated revenues of 65.0 million Swiss francs, reflecting ~6.0% YoY growth at CER. In the United States and Europe markets, Erivedge generated second-quarter revenues of 40.0 million Swiss francs and 18.0 million Swiss francs, respectively. Erivedge is used for the treatment of individuals with advanced basal cell carcinoma.

Advertisement

More From Market Realist